Delivery Order SPE2DB25D3018-SPE2DB25FUYLY
- Not listed
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency awarded a $2,803.18 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL), an extended-release liquid formulation of methylphenidate used in attention-deficit/hyperactivity disorder treatment. This firm fixed-price delivery order, with an ultimate completion date of August 15, 2025, was competitively awarded with no set-aside designation and will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,609.51 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml Suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor on a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 through December 2026, to supply Quillivant XR 25 mg/5 ml suspension in a 150ml quantity. This firm fixed-price delivery order, valued at $1,577.04, was competitively awarded without a set-aside designation and is scheduled for completion by July 31, 2025. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $5,357.13 to AmerisourceBergen Drug Corp for Quillivant XR oral suspension (150mL, 5mg/mL) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of methylphenidate used to treat...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,859.94 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in a 120 mL container. The contract was competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery...
- The Defense Logistics Agency awarded a $1,085.70 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUYLYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (60 mL) with a ceiling value of $1,077.54. This non-competitive, firm fixed-price delivery order was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The product is a liquid formulation of methylphenidate used to treat attention-deficit/hyperactivity disorder and represents a typical pharmaceutical supply need within the federal medical procurement system. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare programs worldwide, including serving the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/8/25 |